Abstract
Medication use during pregnancy is common, yet safety data remain limited, often leading to exaggerated risk perceptions and suboptimal care. Current communication practices are fragmented: product labeling and patient leaflets tend to emphasize potential harms, while specialized resources are underused. We explore the challenges of conveying accurate risk-benefit information and highlight the need for shared decision making. Integrated, evidence-based resources accessible to both healthcare providers and patients can reduce misinformation, improve adherence to essential treatments, and ultimately enhance maternal and child health. The Swiss MAMA-MEDS initiative illustrates how a unified knowledge base can align messaging, address health inequalities, and support patient-centered pregnancy care.
Author supplied keywords
Cite
CITATION STYLE
Winterfeld, U., Hodson, K., Berlin, M., Marin, B., Ceulemans, M., Weber-Schoendorfer, C., … Panchaud, A. (2025). Communicating medication risks in pregnancy: Towards shared decision making. Frontiers in Drug Safety and Regulation, 5. https://doi.org/10.3389/fdsfr.2025.1712216
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.